QPPV.COM KNOWLEDGE ASSESSMENT

Knowledge Assessment: Paediatric Pharmacovigilance

Test your understanding of the concepts covered by GVP Product- or Population-Specific Considerations IV: Paediatric Population.

Question 1 of 10Pass mark: 80%

Question 1 of 10 A child receives a medicinal product and a vaccine within the same period and later develops fever. Which assessment is most appropriate?

Assign causality to the most recently administered product Assign causality to the medicinal product because vaccines are separate from pharmacovigilance Consider timing, background incidence, biological plausibility and the characteristics of each exposure Exclude the case because multiple exposures make assessment impossible

Question 2 of 10 A cluster of overdoses occurs after caregivers confuse two concentrations of a liquid medicine. What should the initial pharmacovigilance assessment primarily investigate?

Whether all cases should automatically be classified as intrinsic product toxicity Whether the concentration, labelling, device or instructions contributed to an administration error Whether spontaneous reports can be excluded because the events were preventable Whether the product should immediately be withdrawn without further assessment

Question 3 of 10 How should an adverse event following off-label paediatric use generally be handled?

It should be disregarded because it cannot inform pharmacovigilance for authorised use It should be treated as proof that the authorised indication is unsafe It should be assessed with the actual indication, dose, age, formulation and route clearly considered It should be included only if the medicine was used within the authorised age range

Question 4 of 10 What is the most appropriate relationship between a paediatric signal-management conclusion and a subsequent RMP decision?

They are identical decisions and should not be documented separately The signal conclusion informs whether the RMP requires reassessment, but the decisions are distinct The RMP should be changed for every isolated paediatric report The RMP is relevant only to adult risks

Question 5 of 10 Why may a short conventional follow-up period be inadequate for a suspected developmental safety concern?

Developmental outcomes may require time to emerge and may have substantial latency Children are never able to provide safety information immediately after exposure Long-term follow-up is required for every paediatric adverse event Short-term adverse events cannot be clinically assessed in children

Question 6 of 10 A paediatric safety result is uncertain because exposure is limited and the outcome is multifactorial. What is the most appropriate regulatory interpretation?

Convert the uncertainty into a confirmed causal risk Conclude that no risk exists because causality cannot be proven Characterise the uncertainty and determine whether additional evidence could reduce it Avoid documenting the issue until definitive evidence becomes available

Question 7 of 10 A caregiver reports that an infant became unusually sleepy and stopped feeding after treatment. What is the most appropriate interpretation of the report at the initial assessment stage?

The observations are clinically irrelevant because the infant cannot describe symptoms The observations may provide important clinical evidence, but they should be distinguished from a causal conclusion The event should automatically be coded as a confirmed product reaction Caregiver observations should replace all clinical information

Question 8 of 10 What is the most appropriate use of adult safety evidence in a paediatric assessment?

Transfer the adult risk estimate directly to children Use adult evidence as mechanistic, pharmacological or class-level context while assessing paediatric differences Replace paediatric evidence whenever adult data are extensive Ignore adult evidence because developmental differences make it irrelevant

Question 9 of 10 Why is background incidence particularly important when evaluating paediatric safety signals?

Paediatric adverse events are always caused by underlying disease Many outcomes occur naturally in children and their frequency varies with age, disease and other factors Background rates are needed only for randomised clinical trials A signal is confirmed whenever the observed number of cases exceeds zero

Question 10 of 10 A product associated with renal toxicity is used in neonates and adolescents. What is the most appropriate population characterisation for the safety assessment?

Use one paediatric category because both groups are below 18 years Use only the prescribed dose because renal function is not relevant to case assessment Consider developmental stage and renal maturation in addition to age and dose Exclude adolescents because their renal physiology is adult-like

QPPV.com

Knowledge Assessment: Paediatric Pharmacovigilance

Cookie Settings